It's official: Pharma faces an aggressive plan for price negotiation on top brands, price-hike rollbacks and more. But does the bill stand a chance?
Months after the FDA demanded Lupin act on failures at an Indian plant, the drugmaker may have known a reckoning was coming. They were right.
Best practices manufacturers can leverage to ensure accurate and timely data is available at launch and beyond
Roche has spent years reprioritizing its manufacturing spending, and as part of that process, it's exiting a small molecule site in Ireland.
New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.
Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.
An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.
After a little more than two years on the job, Alexion CFO Paul Clancy and his “legendary caution” around transactions are out. Is an M&A spree coming?
Biogen plans to test its SMA drug Spinraza at a higher-than-approved dose as Novartis' rival gene therapy Zolgensma picks up traction.
Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…
A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.
